GSK

Glaxosmithkline Plc

Stocks

5 Best Dividend Stocks to Buy Now

There’s no better time than now to invest in dividend stocks.

And some of the best dividend stocks that beat the S&P 500’s average yield of 2.00% can be found in the healthcare sector.

Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a total of $220 billion in dividend cuts between the second and fourth quarters of 2020.

Since then, dividend payments jumped 26% to $471.7 billion.

And dividends paid to investors are expected to pay out $1.39 trillion by the end of the year.

We only have to look at one sector to find the best combination of yields and strong balance sheets.

Read more...

Biotechnology

Read This Before You Play a Single One of the Biotechs Fighting COVID-19

Georgia, South Carolina, and Florida have announced that they are loosening quarantine restrictions; at least 13 more states have announced plans or "roadmaps" to do more or less the same thing.

There's an urgent desire to get "back to normal" as quickly as possible because the social and economic devastation – record unemployment, more than 55,300 deaths, massive lockdowns, shrinking GDP, and of course the virus itself – of the coronavirus pandemic has been so profound.

And this has all happened in a little more than a month. People are understandably anxious to put all this behind them, myself very much included.

But the stakes of "normalcy" are higher than we're being told. The successful reemergence of people into the world will require far more than just repeated reminders to wash your hands and not touch your face.

Social distancing and limited interaction can slow the spread; there's mounting evidence in the United States and other countries that we've done precisely that. But it's far from clear how much those actions could really prevent widespread illness as lockdowns ease and stay-at-home orders are lifted.

Because it's very likely that we won't be truly "safe" until a proven treatment and effective vaccine are available.

The more we learn about this virus, the more we're aware of why its ongoing impact, and the "right" way to reopen the economy, remain so uncertain.

Here's what we do know… Full Story

Here's what we do know... Full Story

Biotechnology

How to Cash In on the Biggest Medical Breakthrough of the Decade

Imagine if all it took to treat a case of cancer was taking out the trash.

Now, I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here's the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as "degraders."

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body's own molecular trash disposal systems.

This is one of the most exciting breakthroughs I've come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

And in a moment, I'm going to reveal a way investors can target the entire class of protein degraders with one savvy move...

Wall Street

This Investing Strategy Is a "Laser-Focused Rocket Ship to Big Profits"

This week I'm spending some time testing the theory from a recent paper on how insider buying and selling affects different bearish and bullish factors.

I'm finding that adding insider data to our stable of numbers-driven market strategies really boosts returns, and more importantly, it does so by avoiding potential problems.

While insider buying does magnify gains somewhat overall, where portfolio returns go into the stratosphere is using insider selling to cancel signals that would otherwise be a buy.

This helps us avoid the big mistakes and keeps the focus of the portfolio on those companies where insiders have been buying.

The results from this combination create a portfolio that's a laser-focused rocket ship to big profits...

Technology

The Answer to Big Pharma's Biggest Problem Could Double Your Money in Just Three Years

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world's largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That's a one-in-ten shot.

With such daunting data, it's no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I've uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector's success.

It's a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure.

And it's been doubling its earnings, on average, every 18 months...

Dow Jones

Dow Jones Industrial Average Rallies Today Ahead of FOMC Decision

The Dow Jones Industrial Average is rallying early Wednesday ahead of today's critical announcement by the Federal Reserve on interest rates.

Despite outrage from President Donald Trump, the U.S. central bank is expected to hike interest rates for the fourth time in 2018, raising concerns that the Fed will put a halt on America's economic expansion and rattle investor confidence for the balance of the year.

Here's everything you need to know about the market today...